Welcome to our dedicated page for Fibrogen SEC filings (Ticker: FGEN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings archive for FibroGen, Inc. (FGEN) provides regulatory documents that trace the company’s evolution into Kyntra Bio, Inc. A Form 8-K filed in January 2026 reports a Certificate of Amendment to the Amended and Restated Certificate of Incorporation, changing the company’s name from FibroGen, Inc. to Kyntra Bio, Inc. The same filing notes that the company’s common stock, formerly trading under the symbol FGEN, began trading on Nasdaq under the symbol KYNB on January 8, 2026, with the CUSIP number unchanged.
Other Form 8-K filings in this archive document key corporate events and financial updates. These include reports on quarterly financial results, amendments to financing agreements, and the completion of the sale of FibroGen International (Hong Kong) Ltd. (FibroGen China) to AstraZeneca Treasury Limited. The filings describe the total consideration for that transaction, the inclusion of all roxadustat assets in China, and the subsequent repayment of a senior secured term loan.
Investors can use these filings to understand how the company presents its business, capital structure, and strategic transactions to regulators. While detailed annual reports (Form 10-K), quarterly reports (Form 10-Q), and insider transaction reports (such as Form 4) are not listed in the provided data, the available 8-Ks illustrate how FibroGen, now Kyntra Bio, communicates material events, including regulatory approvals related to the China divestiture and financial condition updates.
On Stock Titan, these historical FGEN filings are paired with AI-powered tools that help interpret complex disclosures, highlight significant items in event-driven reports, and connect corporate actions—such as the name change, asset sale, and financing amendments—to the broader narrative of the company’s transformation into Kyntra Bio.
FibroGen, Inc. (FGEN) reported Q3 2025 results highlighted by the divestiture of its China operations to AstraZeneca for total consideration of $220.4 million. The company received $210.4 million at closing on August 29, 2025 and used approximately $80.9 million to repay its senior secured term loan facilities, interest, and related fees.
Results reflect discontinued operations for China: income from discontinued operations was $213.8 million in the quarter, including a $52.2 million gain on divestiture. From continuing operations, revenue was $1.1 million and loss was $13.1 million. Net income was $200.6 million, driven by the discontinued operations gain. Cash and cash equivalents were $118.0 million as of September 30, 2025, up from $50.5 million at year-end 2024.
The company effected a 1‑for‑25 reverse stock split on June 16, 2025. Shares outstanding were 4,045,445 as of October 31, 2025. Management now believes existing cash will fund planned operating requirements for at least 12 months following issuance. FibroGen initiated a Phase 2 study of FG‑3246 in mCRPC and aligned with the FDA on key elements of a planned Phase 3 for roxadustat in lower‑risk MDS.
FibroGen, Inc. furnished an 8-K to announce it issued a press release with financial results for the quarter ended September 30, 2025. The press release is provided as Exhibit 99.1.
The company states the information under Item 2.02, including Exhibit 99.1, is not deemed “filed” under the Exchange Act and will not be incorporated by reference into other SEC filings.
FibroGen, Inc. reported receipt of a $6.4 million payment from AstraZeneca. The amount reflects release of the first $6.0 million holdback under their February 20, 2025 share purchase agreement, plus $0.4 million from final net cash adjustments after closing.
This relates to FibroGen’s August 29, 2025 sale of its China operations to AstraZeneca for approximately $220 million, comprised of $85 million in enterprise value and about $135 million in net cash held in China. Of the total, $210 million was paid at closing, with an additional $10.0 million subject to holdbacks: the now-released $6.0 million cash-adjustment holdback and a separate $4.0 million indemnity holdback to be released, net of any claims paid or unresolved, nine months after closing.
David DeLucia, Chief Financial Officer of FibroGen, Inc. (FGEN), reported two dispositions of common stock that were withheld to satisfy tax obligations arising from the vesting of restricted stock units. The Form 4 lists a transaction on 06/06/2025 showing a disposition at a price of $7.8325 and a reported beneficial ownership of 4,594 shares following the transaction. A second reported disposition on 09/06/2025 shows a price of $12.10 and a reported beneficial ownership of 4,541 shares following that transaction. The filer states these shares were withheld by the issuer to cover taxes on RSU vesting. The filing notes a 1-for-25 reverse stock split effective June 16, 2025. The Form 4 is signed by an attorney-in-fact on behalf of the reporting person.
Thane Wettig, listed as CEO and Director of FibroGen, Inc. (FGEN), reported two stock disposals in 2025 and an indirect holding by his spouse. On 06/06/2025 he disposed of 21,487 shares at a reported price of $7.8325, and on 09/06/2025 he disposed of 21,239 shares at $12.10. The filing states these share amounts were withheld by the issuer to satisfy a tax obligation arising from the vesting of restricted stock units.
The form also notes an indirect beneficial ownership of 40 shares by his spouse. A 1-for-25 reverse stock split effective June 16, 2025 is disclosed and the reported share counts and prices reflect that split. The form is signed by an attorney-in-fact on behalf of the reporting person.
FibroGen, Inc. completed the sale of all issued and outstanding equity interests of its subsidiary FibroGen International (Hong Kong) Ltd. to AstraZeneca Treasury Limited on August 29, 2025 for approximately $220 million, closing a previously announced transaction under a Share Purchase Agreement dated February 20, 2025. The deal represents a disposition of assets associated with FibroGen’s China anemia business structure. The company also provided unaudited pro forma condensed consolidated financial information, including a balance sheet as of June 30, 2025 and statements of operations for the year ended December 31, 2024, in Exhibit 99.1 to help illustrate the financial impact of this divestiture.
FibroGen, Inc. reported that it has completed the sale of FibroGen International (Hong Kong) Ltd., including its FibroGen China operations, to AstraZeneca Treasury Limited for total consideration of approximately $220 million. This amount consists of $85 million in enterprise value and about $135 million in net cash held in China, with $6.0 million held back for final cash adjustments and $4.0 million held back for potential indemnity claims.
FibroGen and a subsidiary sold all equity interests in the Hong Kong entity and its China roxadustat assets to AstraZeneca, which has long partnered with FibroGen on roxadustat in greater China and South Korea. FibroGen keeps roxadustat rights in the United States, Canada, Mexico, and other territories not held by AstraZeneca or licensed to Astellas Pharma Inc. At closing, FibroGen repaid its term loan facility with investment funds managed by Morgan Stanley Tactical Value for approximately $81 million.
FibroGen, Inc. announced that Chinese regulators approved the proposed sale of FibroGen International (Hong Kong) Ltd. and its subsidiaries (“FibroGen China”) to AstraZeneca Treasury Limited under a share purchase agreement dated February 20, 2025.
The China State Administration for Market Regulation decided not to prohibit AstraZeneca’s acquisition of FibroGen China, which includes all of FibroGen’s roxadustat assets in China. The transaction is subject to customary closing conditions and deliverables and is expected to close in the third quarter of 2025.
FibroGen and its subsidiary FibroGen China Anemia Holdings, Ltd. will sell all issued and outstanding equity interests of FibroGen International (Hong Kong) Ltd. to AstraZeneca, FibroGen’s long-time commercialization partner for roxadustat in greater China and South Korea. FibroGen will retain rights to roxadustat in the United States, Canada, Mexico, and in markets not already held by AstraZeneca or licensed to Astellas Pharma Inc. in Europe, Japan, and certain other territories.
Armistice Capital, LLC and Steven Boyd report beneficial ownership of 336,000 shares of FibroGen, Inc. common stock, representing 8.31% of the outstanding class based on the issuer's reported share count in its most recent 10-Q. Armistice Capital acts as investment manager to the Master Fund, the direct holder of the shares, and exercises shared voting and dispositive power over the reported securities. Mr. Boyd, as managing member of Armistice Capital, is similarly reported to have shared voting and dispositive power. The Master Fund disclaims direct beneficial ownership due to the investment management arrangement.
FibroGen, Inc. reported condensed consolidated results for the quarter ended June 30, 2025. Total assets were $178.1 million versus $214.5 million at year-end 2024, and the company reported a consolidated total deficit of $202.5 million. For continuing operations, total revenue was $1.35 million for the quarter and $4.09 million for the six months ended June 30, 2025. The company recorded a net loss of $7.6 million for the quarter and $3.0 million for the six-month period; income from discontinued operations was $6.08 million for the quarter and $27.49 million for six months.
The company entered a share purchase agreement to sell FibroGen International to AstraZeneca for $85 million plus the net cash in China, with closing expected in the third quarter of 2025 subject to China SAMR approval. Management disclosed substantial doubt about the company’s ability to continue as a going concern without closing the sale or obtaining additional financing and must satisfy a U.S. cash covenant of $18.75 million. The company has a $75 million senior secured term loan (principal) that is presented as current with maturity in May 2026 and a liability related to the sale of future revenues of approximately $63.0 million.